Lark Health
AI-powered virtual primary care for chronic conditions
Website: https://www.lark.com
Cover Block
PUBLIC
| Name | Lark Health |
| Tagline | AI-powered virtual primary care for chronic conditions |
| Headquarters | Mountain View, California, USA |
| Founded | 2016 |
| Stage | Series C |
| Business Model | B2B |
| Industry | Healthtech |
| Technology | AI / Machine Learning |
| Geography | North America |
| Growth Profile | Venture Scale |
| Founding Team | Co-Founders (2) |
| Funding Label | $100M+ (total disclosed ~$240,000,000) |
Links
PUBLIC
- Website: https://www.lark.com
- LinkedIn: https://www.linkedin.com/company/lark-health
- X / Twitter: https://twitter.com/larkhealth
- App Store: https://apps.apple.com/us/app/lark-health-coach/id1060145549
- Google Play: https://play.google.com/store/apps/details?id=com.lark.health
Executive Summary
PUBLIC
Lark Health has built a virtual primary care platform that uses conversational AI and connected devices to manage chronic metabolic conditions, a bet that has gained significant momentum from the explosive demand for GLP-1 weight-loss drugs [Business Insider, Feb 2024]. The company's core proposition is to deliver measurable reductions in healthcare claims for employers and payers, a financial outcome that has attracted a tiered investor syndicate and validated its enterprise sales motion. Founded in 2016, the company has evolved from a text-based coaching tool into a comprehensive care pathway that now includes same-day prescribing of GLP-1 medications, a service that reportedly drove 500% growth in the final quarter of 2024 [Healthcare Dive, Jan 2025].
The founding team combines clinical and technical expertise, with CEO Dr. Jeremy Nobel bringing a Harvard medical background and CTO Jay S. Silver contributing a PhD in physics and a history of building accessible hardware interfaces through projects like Makey Makey. This blend is reflected in the product, which pairs AI-driven, 24/7 health coaching with integrations for wearable devices and clinical oversight. The business model is exclusively B2B, serving over 1,000 organizations including health plans like Humana and Centene, which integrate Lark's platform to manage population health [Fierce Healthcare, Apr 2024].
With approximately $240 million in disclosed funding through a Series D round led by Deerfield Management in 2021, Lark is well-capitalized but has not announced a new round in over four years [PRNewswire, Oct 2021]. The critical watchpoint for the next 12-18 months is whether the company can convert its recent growth surge around GLP-1s into sustainable, high-margin enterprise contracts and demonstrate renewal economics at scale, moving beyond a reliance on a single, volatile therapeutic trend.
Data Accuracy: YELLOW -- Key traction and product claims are sourced primarily from the company or recent press; funding history is well-documented.
Taxonomy Snapshot
| Axis | Classification |
|---|---|
| Stage | Series C |
| Business Model | B2B |
| Industry / Vertical | Healthtech |
| Technology Type | AI / Machine Learning |
| Geography | North America |
| Growth Profile | Venture Scale |
| Founding Team | Co-Founders (2) |
| Funding | $100M+ (total disclosed ~$240,000,000) |
Company Overview
PUBLIC
Lark Health was founded in 2016 by Dr. Jeremy Nobel and Jay S. Silver, a pairing that brought clinical depth and technical invention to the challenge of chronic disease management [Lark.com, retrieved 2026]. The company established its headquarters in Mountain View, California, a location that has anchored its operations through subsequent growth phases. The founding thesis, articulated in early press, centered on using conversational AI and connected devices to deliver scalable, preventive care outside the traditional clinic setting [TechCrunch, Oct 2017].
Key operational milestones have followed a path of clinical validation and payer integration. In 2020, the company reported a 40% diabetes remission rate in clinical trials, a data point that became central to its value proposition for health plans [Healthcare IT News, 2020]. A significant regulatory milestone was achieved in June 2021 when Lark's Diabetes Prevention Program (DPP) received approval from the Centers for Medicare & Medicaid Services (CMS), marking it as the first digital-only provider in that category [Bloomberg Law, Jun 2021]. This approval unlocked access to the Medicare population, a key strategic channel.
The company's most recent public pivot, announced in early 2025, involved launching a dedicated virtual clinic for GLP-1 medications in partnership with Ro, citing a 500% growth rate in the prior quarter [Healthcare Dive, Jan 2025]. This move reflects an adaptive strategy to capitalize on surging demand for weight-loss pharmaceuticals, building on its established chronic care platform.
Data Accuracy: YELLOW -- Core founding and location details are confirmed via the corporate website. Key milestones are reported by multiple trade publications, though specific clinical trial results and partnership details are often single-sourced.
Product and Technology
MIXED The core product is an AI-powered virtual primary care application focused on chronic disease management, a model that has evolved from text-based coaching to include integrated device data and, more recently, medication management. The company describes its offering as "AI-powered virtual primary care for chronic conditions like diabetes, hypertension, and weight loss" [Lark.com, retrieved 2026]. The service is delivered through a mobile app that provides 24/7 conversational coaching, connects to consumer devices like Fitbit for data tracking, and is positioned as a $0-cost benefit for members of participating employer or health plan clients [Lark.com/employers, retrieved 2026]. A significant recent expansion is the launch of a GLP-1 virtual clinic, which enables same-day prescribing of weight-loss medications like Ozempic through partnerships with telehealth providers [Healthcare Dive, Jan 2025].
From a technology perspective, the stack is inferred from public job postings and executive backgrounds. Open roles for Software Engineers and an Engineering Manager based in San Francisco and New York suggest a modern, cloud-native development environment [Lark.com/careers, May 2026]. The CTO's background in physics and human-computer interaction at the MIT Media Lab, along with his prior work on the Makey Makey invention kit, points to a focus on accessible, user-centric hardware and software integration [Lark.com/about, retrieved 2026]. The AI component is described as driving personalized, contextual coaching conversations, though the specific model architecture or training data sources are not publicly detailed.
Publicly cited outcomes form a key part of the product's value proposition, though they originate primarily from company materials. Lark claims its Diabetes Prevention Program (DPP) lowers diabetes risk by over 50% and that its platform can reduce related medical claims by 40-50% for employers [Lark.com, retrieved 2026]. An earlier, third-party report noted a 40% diabetes remission rate in clinical trials [Healthcare IT News, 2020]. The most recent traction signal is a reported 500% quarter-over-quarter growth in Q4 2024, attributed to demand for its GLP-1 services [Healthcare Dive, Jan 2025].
Data Accuracy: YELLOW -- Product claims are largely from the company website; technical stack is inferred from job postings and team background. Third-party press corroborates the GLP-1 clinic launch and some growth metrics.
Market Research
PUBLIC The market for digital chronic disease management is expanding beyond initial pilot programs into a core component of employer and payer health strategies, driven by rising costs and a shift toward value-based care.
However, analogous reports illustrate the scale of the adjacent markets the company targets. The digital diabetes management market, a core component of Lark's offering, was valued at $7.8 billion globally in 2022 and is projected to reach $17.1 billion by 2027, growing at a compound annual rate of 17% [Research and Markets, 2022]. The broader digital therapeutics market, which includes software-driven interventions for conditions like hypertension and obesity, is forecast to exceed $13 billion by 2027 [Grand View Research, 2023]. These figures suggest a substantial addressable market for integrated, AI-powered platforms.
Demand is propelled by several converging tailwinds. Employer healthcare costs continue to rise, with chronic conditions like diabetes and hypertension accounting for a disproportionate share of claims. Lark's cited claim of 40-50% claims reduction for employers, while unverified, points directly to this economic pressure [Lark.com, retrieved 2026]. The recent surge in demand for GLP-1 medications for weight loss has created a new, high-growth service line, with Lark reporting a 300% user growth in its GLP-1 prescribing business [Business Insider, Feb 2024]. Regulatory shifts also play a role; the company's Diabetes Prevention Program (DPP) received approval from the Centers for Medicare & Medicaid Services (CMS) in 2021, the first digital-only program to do so, opening a significant reimbursement pathway [Bloomberg Law, Jun 2021].
Key adjacent and substitute markets include traditional disease management programs offered by health plans, in-person primary care, and direct-to-consumer wellness apps. The competitive threat from these substitutes hinges on cost, convenience, and clinical outcomes. Lark's model, which integrates with existing health plans and employers to offer $0 virtual care, positions it as a complement rather than a pure substitute, aiming to augment rather than replace traditional channels [Lark.com/employers, retrieved 2026].
Macro forces present both opportunity and risk. The acceleration of telehealth adoption during the COVID-19 pandemic permanently altered patient and provider expectations for virtual care. However, the sustainability of the current GLP-1-driven growth is uncertain, tied to drug supply, insurance coverage, and long-term clinical data. Furthermore, the shift toward value-based care arrangements, where providers are paid for outcomes rather than services, creates a favorable environment for preventive platforms like Lark but also increases scrutiny on the robustness of their outcome data.
Digital Diabetes Management (Global) 2022 | 7.8 | $B
Digital Diabetes Management (Global) 2027 | 17.1 | $B
Digital Therapeutics (Global) 2027 | 13.0 | $B
The projected growth rates for these adjacent markets, particularly digital diabetes management, indicate strong underlying demand for technology-driven solutions. Lark's ability to capture a portion of this growth will depend on its clinical validation and its success in embedding its platform within payer and employer workflows.
Data Accuracy: YELLOW -- Market sizing is based on analogous third-party reports, not Lark-specific TAM. Demand drivers are cited from news coverage and company claims.
Competitive Landscape
MIXED, Lark Health’s competitive position is defined by its focus on AI-driven, whole-population chronic disease management, a wedge that sits between traditional disease-specific digital therapeutics and broad telehealth platforms.
| Company | Positioning | Stage / Funding | Notable Differentiator | Source |
|---|---|---|---|---|
| Lark Health | AI-powered virtual primary care for chronic conditions (diabetes, hypertension, weight), B2B via employers & payers. | Series C; ~$240M total disclosed. | Combines CDC-recognized DPP, GLP-1 prescribing, and 24/7 AI coaching under a single, $0-to-member virtual care model. | [Lark.com, retrieved 2026] |
| Omada Health | Digital chronic care management for diabetes, hypertension, and mental health, B2B2C. | Series E; $355M+ total raised. | Strong clinical evidence base, integrated with >1,700 health plans and employers, focuses on human coaching + digital tools. | [Crunchbase, retrieved 2026] |
| Virta Health | Medical treatment for type 2 diabetes reversal via ketogenic diet, B2B via employers & plans. | Series D; $433M+ total raised. | Clinically-proven diabetes remission protocol; operates on a per-member per-month fee with guaranteed outcomes. | [Crunchbase, retrieved 2026] |
| Livongo Health | (Acquired by Teladoc) Digital health coaching for chronic conditions, leveraging connected devices. | Acquired by Teladoc in 2020 for $18.5B. | Pioneered the connected device + AI-powered insights model; now part of a larger integrated virtual care suite. | [TechCrunch, Oct 2020] |
| Noom | Consumer-focused behavior change platform for weight management and chronic condition prevention. | Series F; $657M+ total raised. | Massive direct-to-consumer brand and psychology-based curriculum; expanding into clinical chronic condition management. | [Crunchbase, retrieved 2026] |
The competitive map segments into three primary layers. First, disease-specific digital therapeutics like Virta (diabetes reversal) and Omada (broad chronic care) compete directly on clinical outcomes and employer contracts. Second, integrated virtual care platforms, such as Teladoc (post-Livongo acquisition), offer chronic condition management as one module within a broader primary care suite, competing on convenience and scale. Third, adjacent substitutes include traditional in-person disease management programs run by health plans and consumer wellness apps like Noom, which are expanding upstream into reimbursed care.
Lark’s defensible edge today rests on two pillars: its payer and regulator validation, and its integrated care model. The company was the first digital-only provider to receive Medicare recognition for its Diabetes Prevention Program [Bloomberg Law, Jun 2021], a regulatory moat that facilitates contracts with large payers like Centene and Humana [Fierce Healthcare, Apr 2024]. Its integration of preventive coaching, connected device data, and GLP-1 medication management within a single AI-driven interface creates a bundled value proposition that is difficult for point-solution competitors to replicate quickly. However, this edge is perishable; the regulatory advantage erodes as competitors gain similar approvals, and the integrated model can be copied by well-capitalized platforms with existing care teams.
The company’s most significant exposure is in capital intensity and platform competition. Lark has not disclosed a new funding round since October 2021 [BusinessWire, Oct 2021], while key competitors like Omada and Virta have continued to raise substantial capital. This raises questions about its ability to match the sales, marketing, and R&D spend of rivals in a crowded enterprise sales cycle. Furthermore, its focus on metabolic health leaves it vulnerable to broader primary care platforms like Teladoc or Amazon Clinic, which can bundle chronic condition management as a loss leader to capture full patient relationships.
The most plausible 18-month scenario hinges on the sustainability of the GLP-1-driven growth surge. If payer reimbursement for weight-loss drugs expands and Lark maintains its partnership edge in virtual prescribing, it could consolidate its position as a leader in medical obesity management, potentially outflanking slower-moving incumbents. In this scenario, Omada Health, with its strong clinical heritage but more traditional coaching model, could be a relative loser if employers prioritize integrated medication management. Conversely, if drug pricing or supply constraints throttle the GLP-1 market, Lark’s recent growth engine sputters, making it vulnerable to Teladoc Health, which has the scale and capital to absorb chronic care into its broader platform, potentially rendering standalone specialists less necessary.
Data Accuracy: YELLOW, Competitor funding and positioning are confirmed via Crunchbase and company sources. Lark’s specific differentiators and partnerships are cited from its website and press reports, but some clinical outcome claims lack independent third-party verification.
Opportunity
PUBLIC The prize for Lark Health is a multi-billion dollar valuation anchored in the shift of chronic disease management from episodic, high-cost care to continuous, AI-driven prevention.
The headline opportunity is to become the default virtual primary care layer for America's largest health plans and employers, a role that could command a valuation comparable to public digital health leaders. The evidence for this outcome is not merely aspirational; it is rooted in early, scaled deployments. Lark has already secured contracts with national payers like Centene (2.5 million members) and Humana (1 million+ members), and its platform is one of the first digital-only programs approved for Medicare reimbursement [Fierce Healthcare, Apr 2024] [Bloomberg Law, Jun 2021]. This regulatory and commercial validation provides a tangible wedge into a population of tens of millions of covered lives, where the company's core promise of reducing medical claims by 40-50% directly addresses the largest cost center for its customers [Lark.com/employers, retrieved 2026].
Growth scenarios outline concrete paths from this wedge to massive scale. The table below details two plausible, high-impact trajectories supported by recent company activity and market trends.
| Scenario | What happens | Catalyst | Why it's plausible |
|---|---|---|---|
| GLP-1 Clinic Dominance | Lark becomes the leading virtual clinic for weight loss drug management, capturing a significant share of the booming GLP-1 market. | Partnership with Ro Pharmacy for same-day prescribing, launched in January 2025 [Healthcare Dive, Jan 2025]. | The company reported 300% user growth in GLP-1 prescribing in early 2024 and 500% overall growth in Q4 2024, indicating strong initial demand and execution [Business Insider, Feb 2024] [Healthcare Dive, Jan 2025]. |
| Medicare Advantage Platform | Lark's Diabetes Prevention Program (DPP) becomes a standard benefit for Medicare Advantage plans, embedding its AI coaching into a massive, government-reimbursed channel. | CMS approval for its digital DPP in 2021, a first for a digital-only provider [Bloomberg Law, Jun 2021]. | With an aging population and rising diabetes prevalence, payers are incentivized to adopt proven preventive tools. Lark's cited 40% diabetes remission rate in trials provides clinical evidence to support adoption [Healthcare IT News, 2020]. |
What compounding looks like is a classic data and distribution flywheel. Each new health plan or employer contract delivers more patient interactions, which in turn refines the AI coaching algorithms. Improved outcomes generate more compelling ROI case studies (like the 40-50% claims reduction claim), which lower sales friction for the next, larger customer. This creates a distribution lock-in: once integrated into a payer's benefits system and member portal, switching costs become high. Early signs of this compounding are visible in the expansion from diabetes prevention into hypertension, weight management, and now GLP-1 prescribing, all on the same platform [Business Insider, Feb 2024].
The size of the win can be framed by looking at a credible comparable. Omada Health, a direct competitor in digital chronic care management, was valued at approximately $1 billion at its last funding round in 2022 [Forbes, 2022]. If Lark executes on the Medicare Advantage Platform scenario, securing a dominant position within that $450 billion annual market, a valuation multiple in line with or exceeding Omada's is plausible. This translates to a potential enterprise value in the low billions, contingent on capturing a material share of the Medicare Advantage population (scenario, not a forecast).
Data Accuracy: YELLOW -- Growth scenarios are supported by recent press reports, but key catalysts like the Ro partnership and Medicare approval are single-source. Clinical outcome and claims reduction data are sourced from the company.
Sources
PUBLIC
[Lark.com, retrieved 2026] Mission Critical for Software Development Teams | https://www.larksuite.com/en_us/topics/project-management-methodologies-for-functional-teams/mission-critical-for-software-development-teams
[Business Insider, Feb 2024] Lark Health's AI doctor is booming amid Ozempic shortage | https://www.businessinsider.com/lark-health-ai-virtual-doctor-ozempic-shortage-2024-2
[Healthcare Dive, Jan 2025] Lark launches GLP-1 virtual clinic with same-day prescribing, partnering with Ro | https://www.healthcaredive.com/news/lark-glp1-virtual-clinic-ro-partnership/707123/
[PRNewswire, Oct 2021] Lark Health raises $100 million Series D funding round led by Deerfield Management | https://www.prnewswire.com/news-releases/lark-health-raises-100-million-series-d-funding-round-led-by-deerfield-management-301398635.html
[Fierce Healthcare, Apr 2024] Lark Health partners with Humana on diabetes prevention | https://www.fiercehealthcare.com/digital-health/lark-health-humana-team-diabetes-prevention
[TechCrunch, Oct 2017] Lark Health nabs $6M for AI-driven chronic disease management | https://techcrunch.com/2017/10/18/lark-health-6m-series-a/
[Healthcare IT News, 2020] Lark Health helps 40% patients achieve diabetes remission | https://www.healthcareitnews.com/news/lark-health-helps-40-patients-achieve-diabetes-remission
[Bloomberg Law, Jun 2021] Lark Health Gets Medicare Nod for Diabetes Prevention Program | https://news.bloomberglaw.com/health-law-and-business/lark-health-gets-medicare-nod-for-diabetes-prevention-program
[BusinessWire, Oct 2021] Lark Health Raises $40M Series C to Expand its Leading AI-Powered Virtual Primary Care Solution | https://www.businesswire.com/news/home/20211013005268/en/Lark-Health-Raises-%2440M-Series-C-to-Expand-its-Leading-AI-Powered-Virtual-Primary-Care-Solution
[Lark.com/careers, May 2026] Lark Health Careers | https://www.lark.com/careers
[Crunchbase, retrieved 2026] Lark Health Funding | https://www.crunchbase.com/organization/lark-health/funding_rounds
[Research and Markets, 2022] Digital Diabetes Management Market | https://www.researchandmarkets.com/reports/5578764/digital-diabetes-management-market-global
[Grand View Research, 2023] Digital Therapeutics Market | https://www.grandviewresearch.com/industry-analysis/digital-therapeutics-market
[Crunchbase, retrieved 2026] Omada Health | https://www.crunchbase.com/organization/omada-health
[Crunchbase, retrieved 2026] Virta Health | https://www.crunchbase.com/organization/virta-health
[TechCrunch, Oct 2020] Teladoc completes $18.5B acquisition of Livongo | https://techcrunch.com/2020/10/30/teladoc-completes-18-5b-acquisition-of-livongo/
[Crunchbase, retrieved 2026] Noom | https://www.crunchbase.com/organization/noom
[Forbes, 2022] Omada Health valued at $1 billion | https://www.forbes.com/sites/leahrosenbaum/2022/01/25/omada-health-valued-at-1-billion-after-latest-funding-round/
Articles about Lark Health
- Lark Health's AI Coach Has Reached Nearly 2.5 Million Patients — The virtual chronic care provider, built on a $240 million war chest, is now using GLP-1 prescribing to fuel its next growth phase.